Current Advances and Future Strategies for BCL-2 Inhibitors: Potent Weapons against Cancers.

Xu, Jiaxuan; Dong, Xiaoqing; Huang, David C S; Xu, Peipei; Zhao, Quan; Chen, Bing

Xu, Jiaxuan; Dong, Xiaoqing; Huang, David C S; Xu, Peipei; Zhao, Quan; Chen, Bing.

Afiliación

Xu J; Department of Hematology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, China-Australia Institute of Translational Medicine, School of Life Sciences, Nanjing University, Nanjing 210008, China.
Dong X; Department of Hematology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, China-Australia Institute of Translational Medicine, School of Life Sciences, Nanjing University, Nanjing 210008, China.
Huang DCS; Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC 3052, Australia.
Xu P; Department of Medical Biology, University of Melbourne, Melbourne, VIC 3010, Australia.
Zhao Q; Department of Hematology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, China-Australia Institute of Translational Medicine, School of Life Sciences, Nanjing University, Nanjing 210008, China.
Chen B; Department of Hematology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, China-Australia Institute of Translational Medicine, School of Life Sciences, Nanjing University, Nanjing 210008, China.

Cancers (Basel) ; 15(20)2023 Oct 12.

Article en En | MEDLINE | ID: mdl-37894324

Palabras clave

BCL-2 inhibitor; cancers; combination therapy; genetic mutations; venetoclax

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google